Seaport Therapeutics files for a $100 million Nasdaq IPO, advancing Phase 2b and Phase 1 neuropsychiatric programs using its Glyph prodrug platform

Seaport Therapeutics filed with the SEC for a potential $100 million initial public offering and plans to list on Nasdaq under the ticker SPTX. The company is developing oral neuropsychiatric therapies for conditions including depression and anxiety. Its platform, the Glyph lymphatic-targeting prodrug technology, is designed to improve oral bioavailability and reduce first-pass metabolism, aiming to differentiate product candidates from clinically validated mechanisms. Lead programs include GlyphAllo in Phase 2b for major depressive disorder and GlyphAgo in Phase 1 for generalized anxiety disorder, with additional preclinical candidates focused on depressive and related CNS disorders. Seaport was founded in 2024, filed confidentially on November 21, 2025, and the offering lists Goldman Sachs, J.P. Morgan, Leerink Partners, Citi, and Stifel as joint bookrunners.